Nanoemulsion‐based transdermal delivery of third‐generation steroidal and non‐steroidal aromatase inhibitors in preclinical models
Cell Proliferation · 2025
DOI: 10.1111/cpr.13753 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, 2025. Verfasst von Lanyang Gao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, Academician (Expert) Workstation of Sichuan Province, Department of Ge…. Hauptthemen laut MEDLINE: Aromatase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Foundation of Sichuan Province, China, Scientific research project of the education department of Sichuan Province.
Abstract (Originalsprache)
Aromatase inhibitors are effective in treating hormone receptor‐positive breast cancer, particularly in postmenopausal women. However, the challenges of inconsistent dissolution, variable absorption and side effects with oral administration persist. To address these issues, transdermal delivery has emerged as a viable alternative. In our study, we have developed nanoemulsion‐based transdermal creams containing third‐generation aromatase inhibitors Exemestane (EXE) or Letrozole (LE) and evaluated their toxicity, anti‐tumour effects and androgenic potency using preclinical models including Bama minipigs, DMBA‐induced breast cancer rats and orchidectomized male rats. The results of our study are significant, suggesting that both creams effectively penetrated the skin, demonstrating an impressive anti‐breast cancer effect. Importantly, EXE cream had no organ toxicity at the tested dose, providing a reassuring safety profile for its use. In contrast, LE cream displayed reversible toxicity from drug molecule itself in animals at the given dose, dissipating after 3 weeks of withdrawal and recovery. This study establishes a solid foundation for the safe clinical use of third‐generation aromatase inhibitors. It highlights transdermal creams as a promising drug delivery carrier for administering them.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Metabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, Academician (Expert) Workstation of Sichuan Province, Department of General Surgery (Hepatopancreatobiliary Surgery), Fundamental and Clinic…
- School of Chemical Science and Engineering, Tongji University, Shanghai, China.
- Department of Laboratory Medicine/Sichuan Medical Laboratory Clinical Medicine Research Center, Innovation Institute for Integration of Medicine and Engineering, West China Hospital, Sichuan University, Chengdu, China.
- School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules and National Center for Translational Medicine (Shanghai), Shanghai Jiao Tong University, Shanghai, China.
ORCID-Profile: Lanyang Gao, Yao Luo
Förderung
- National Natural Science Foundation of China
- Science and Technology Foundation of Sichuan Province, China
- Scientific research project of the education department of Sichuan Province
Zitieren
APA
Gao, L., Gao, L., Huang, S., Sun, L., Li, M., Shen, C., Chen, Y., Tan, R., Chen, Y., Zhan, C., Wieland, F. H., Liu, Y., Zhang, Y., & Luo, Y. (2025). Nanoemulsion‐based transdermal delivery of third‐generation steroidal and non‐steroidal aromatase inhibitors in preclinical models. Cell Proliferation. https://doi.org/10.1111/cpr.13753
Vancouver
Gao L, Gao L, Huang S, Sun L, Li M, Shen C, et al. Nanoemulsion‐based transdermal delivery of third‐generation steroidal and non‐steroidal aromatase inhibitors in preclinical models. Cell Proliferation. 2025. doi:10.1111/cpr.13753
BibTeX
@article{Gao2025,
author = {Gao, Lanyang and Gao, Lin and Huang, Shiyao and Sun, Lei and Li, Mei and Shen, Chen and Chen, Youyou and Tan, Ruihao and Chen, Yuji and Zhan, Chengguo and Wieland, Frank Heinrich and Liu, Yingying and Zhang, Yinan and Luo, Yao},
title = {Nanoemulsion‐based transdermal delivery of third‐generation steroidal and non‐steroidal aromatase inhibitors in preclinical models},
journal = {Cell Proliferation},
year = {2025},
doi = {10.1111/cpr.13753}
}
EUVIMED